A Randomized, Single-blind, Dose-Ranging Study to Evaluate Immunogenicity, Safety and Tolerability of Different Formulations of Adjuvanted and Non Adjuvanted Cell-derived, Inactivated Novel Swine Origin A/H1N1 Monovalent Subunit Influenza Virus Vaccine in Healthy Subjects From 6 Months to 17 Years of Age.

Trial Profile

A Randomized, Single-blind, Dose-Ranging Study to Evaluate Immunogenicity, Safety and Tolerability of Different Formulations of Adjuvanted and Non Adjuvanted Cell-derived, Inactivated Novel Swine Origin A/H1N1 Monovalent Subunit Influenza Virus Vaccine in Healthy Subjects From 6 Months to 17 Years of Age.

Completed
Phase of Trial: Phase III

Latest Information Update: 21 Oct 2014

At a glance

  • Drugs Influenza A virus vaccine-H1N1 (Primary)
  • Indications Influenza A virus H1N1 subtype
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors Novartis Vaccines
  • Most Recent Events

    • 24 Mar 2012 Trial status is recruting in Netherlands as reported by European Clinical Trials Database record.
    • 11 Oct 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 23 Jun 2011 Planned end date changed from 1 Apr 2011 to 1 Aug 2011 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top